astrazeneca plc (AZN:London)
Transactions by ASTRAZENECA PLC (AZN) in the last 6 months
ADC Therapeutics Sarl announced that it has received $80 million in an equity round of funding on September 2, 2015. The transaction included participation from new European and US-based investors and existing investors, Auven Therapeutics Management L.L.L.P and AstraZeneca PLC.
Auven Therapeutics Management L.L.L.P
AstraZeneca PLC (LSE:AZN) entered into an agreement to acquire Global rights of HTL-1071 from Heptares Therapeutics Ltd. for $510 million on August 6, 2015. Under the terms of an agreeement, Heptares will receive an upfront payment of $10 million and is eligible to receive additional, significant near term milestone payments based on agreed pre-clinical and/or clinical events up to the maximum of $500 million, as well as up to double-digit tiered royalties on net sales. ...
Genzyme Corporation entered into a definitive agreement to acquire Caprelsa from AstraZeneca PLC (LSE:AZN) for $300 million on July 27, 2015. The deal value includes an upfront payment of $165 million and further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. Caprelsa reported global product sales of $48 million in 2014. The transaction is subject to closing conditions, ...
Entasis Therapeutics announced that it has received $40 million in its series A round of funding from AstraZeneca PLC in March 2015.
|3M Co||$141.74 USD||+0.50|
|BASF SE||€70.77 EUR||+0.01|
|Biogen Inc||$301.63 USD||-2.58|
|Eli Lilly & Co||$81.60 USD||-0.21|
|Valeant Pharmaceuticals International Inc||C$301.25 CAD||-6.75|
|View Industry Companies|